Randomized controlled trials evaluating glucagon-like peptide 1 receptor agonists (such as liraglutide or semaglutide) have shown that these agents can lower the occurrence of cardiovascular events in patients with type 2 diabetes, particularly in individuals with diagnosed CVDs or those at high risk of CVDs [99,100]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.